Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
146.2 USD | +0.25% |
|
-1.74% | -6.75% |
06-28 | Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial | MT |
06-28 | J&J Unit's Rybrevant Combo Gets EU Approval | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-6.75% | 352B | |
+55.32% | 815B | |
+44.05% | 641B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- J&J Unit's Rybrevant Combo Gets EU Approval